TherapeuticsMD (TXMD) Reports In-Line Q2 EPS

TherapeuticsMD (NASDAQ: TXMD) reported Q2 EPS of ($0.11), in-line with the analyst estimate of ($0.11). Revenue for the quarter came in at $23 million versus the consensus estimate of $22.11 million.

For earnings history and earnings-related data on TherapeuticsMD (TXMD) click here.

You May Also Be Interested In

• Baird on Nurix (NRIX) Earnings Amid 7% Drop: '2Q Print Solid as Breadth of Development Expands'
• What Delta’s report tells investors in American and United
• Goldman Sachs reports global fund inflows for week of July 8